(NASDAQ: LAB) Standard Biotools's forecast annual revenue growth rate of 1.53% is not forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 7.3%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.23%.
Standard Biotools's revenue in 2026 is $84,597,000.On average, 3 Wall Street analysts forecast LAB's revenue for 2026 to be $32,711,629,177, with the lowest LAB revenue forecast at $31,739,996,627, and the highest LAB revenue forecast at $34,007,139,243. On average, 3 Wall Street analysts forecast LAB's revenue for 2027 to be $33,346,036,530, with the lowest LAB revenue forecast at $31,586,105,734, and the highest LAB revenue forecast at $35,491,087,137.
In 2028, LAB is forecast to generate $34,908,892,765 in revenue, with the lowest revenue forecast at $32,971,123,769 and the highest revenue forecast at $37,256,514,037.